EGFR and neoplasm: FDA-approved mAbs such as rituximab (anti-CD20), trastuzumab (anti-HER2), and cetuximab (anti-HER1/anti-EGFR) used in lymphoma, breast cancer, head and neck, and colorectal carcinomas, respectively, not only block tumor cell signaling but also induce innate and adaptive antitumor immunity (Ferris et al., 2010).